Gougerot-Sjögren

Gougerot-Sjögren

  
Theander E et al. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36 Lire le résumé
Nocturne G et al. Rheumatoid Factor and Disease Activity. Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. avr 2016;68(4):977‑85.Lire le résumé
Baer AN et al. Association of Anticentromere Antibodies. With More Severe Exocrine Glandular Dysfunction in Sjögren’s Syndrome: Analysis of the Sjögren’s. International Collaborative Clinical Alliance Cohort. Arthritis Care Res. oct 2016;68(10):1554‑9Lire le résumé
Bowman SJ et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1440–50.Lire le résumé
Bootsma H et al. Editorial: Rituximab in the Treatment of Sjögren’s Syndrome: Is It the Right or Wrong Drug? Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1346–9.Lire le résumé
Bodewes ILA, Gottenberg J-E, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine
treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER
randomized trial. Rheumatology [Internet]. 25 juin 2019 [cité 23 juill 2019]; Disponible sur:
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez242/5523045
Lire le résumé